Engineered immune cells take on Hard-to-Treat brain cancers
NCT ID NCT02208362
First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This early-stage trial tests a personalized immunotherapy for people with malignant glioma that has returned or not responded to standard treatment. The patient's own T-cells are collected, genetically modified in a lab to recognize and attack glioma cells, and then infused back into the brain. The main goals are to find a safe dose and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T-cells (CAR T-cells) targeting IL13Rα2
- What this could lead to
- If successful, this could lead to a new treatment option for patients with recurrent or treatment-resistant malignant glioma, potentially improving tumor control.
- What could go wrong
- This is an early Phase 1 trial focused on safety, so it is not yet known if the treatment will effectively shrink tumors. Side effects, including severe immune reactions, are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors